Global Erythropoiesis-Stimulating Agents Market by Product Type (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Epoetin-Theta and Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta), By Application (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural diseases and Others),By Distribution Channel (Offline Channel and Online Channel) and By Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa)

Global Erythropoiesis-Stimulating Agents Market likely to drive by the upsurge in the number of cancer patients and the surge in the incidence of tumor-related anemia
 
 The global Erythropoiesis-Stimulating Agents Market projected to grow with a CAGR 10.3% during the predicted period 2019-2027, on account of rising demand for efficient drugs to control the effects of impaired production of the molecule erythropoietin. Additionally, the global incidence of chronic kidney disease has increased dramatically, and chronic kidney disease has become a public health problem in the world. The rapidly growing demand for Erythropoiesis-Stimulating Agents due to the rising prevalence of chronic kidney disease and cancer and increasing demand for cheaper erythropoietin drugs leads to robust the global erythropoiesis-stimulating agent market in the future timeline. According to WHO 2015 study estimated that 1.2 million people died from kidney failure, an increase of 32% since 2005. Additionally, each year, around 1.7 million people die from acute kidney injury.
 
 A rapid increase in the number of patients suffering from anemic condition induced due to cancer, HIV, ESRD treatment expected to trigger the global erythropoiesis-stimulating agent market. Recombinant erythropoietin is the primary drug for the treatment of renal anemia and tumor-related anemia. With the significant increase in the global population, changes in age and epidemiological trends have significantly increased the incidence of chronic kidney disease worldwide along with upsurge in the number of cancer patients and the incidence of tumor-related anemia. The World Health Organization expects new global developments over the next 20 years. The number of cancer cases will increase by 70%, from 14 million in 2012 to 18.1 million in 2018 and 24 million in 2035.
 
 Product Type Overview in the Global Erythropoiesis-Stimulating Agents Market
 Based on Product Type, the global Erythropoiesis-Stimulating Agents Market categorized into Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Epoetin-Theta, and Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta). The Epoetin Alfa segment expected to dominate the market during the forecast period, 2019-2027 as a greater number of products are approved for prescription in this segment as compared to anemia caused by renal disorders. Darbepoetin Alfa will drive by its application for patients on kidney dialysis or those not on dialysis. Darbepoetin alfa used to treat severe cancer affected anemia patients.
 
 Application Overview in the Global Erythropoiesis-Stimulating Agents Market
 Based on the application, the Global Erythropoiesis-Stimulating Agents Market classified into Cancer, Renal Disorders, Anti-retroviral Treatment, Neural diseases, and others. The Cancer segment is likely to dominate the market, 2019-2027. Due to the application of Erythropoiesis-Stimulating Agents for the treatments for various chronic diseases, like chronic kidney disease (CKD), cancer, neural, and HIV infections.
 
 Distribution Overview in the Global Erythropoiesis-Stimulating Agents Market
 Based on the distribution channel, offline channels expected to dominate the Global Erythropoiesis-Stimulating market in the estimated period, 2019-2027, owing to the easy availability of Erythropoiesis-Stimulating Agents drugs on conventional distribution channels such as pharmacies at the hospital, ambulatory surgical centers, and retail pharmacies.
 
 Regional Overview in the Global Erythropoiesis-Stimulating Agents Market
 By geography, the Global Erythropoiesis-Stimulating Agents Market segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America anticipated generating maximum revenue by 2027 owing to the increasing prevalence of diseases, such as cancer and kidney coupled with the availability of advanced technologies & the presence of research institutes and the rising initiatives by government and private organizations.
 
 Global Erythropoiesis-Stimulating Agents Market: Competitive Landscape
 Companies such as Biocon, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals, Amgen Inc., Hoffmann-La Roche, Biosidus, Thermo Fisher Scientific, F. Hoffmann La Roche, Pfizer, and Ranbaxy Laboratories Ltd are the key players in the Global Erythropoiesis-Stimulating Agents Market.

Global Erythropoiesis-Stimulating Agents Market
 Report Content
 1. Research Strategic Development
 1.1. Market Modelling
 1.2. Product Analysis
 1.3. Market Trend and Economic Factors Analysis
 1.4. Market Segmental Analysis
 1.5. Geographical Mapping
 1.6. Country Wise Segregation
 2. Research Methodology
 2.1. Identification of Target Market
 2.2. Data Acquisition
 2.3. Refining of Data/ Data Transformations
 2.4. Data Validation through Primary Techniques
 2.5. Exploratory Data Analysis
 2.6. Graphical Techniques/Analysis
 2.7. Quantitative Techniques/Analysis
 2.8. Visual Result/Presentation
 3. Executive Summary
 4. Market Insights
 4.1. Supply Chain Analysis
 4.2. Economic Factor Analysis
 4.2.1. Drivers
 4.2.2. Trends
 4.2.3. Opportunities
 4.2.4. Challenges
 4.3. Technological Landscape
 4.4. Competitors & Product Analysis
 4.5. Policy & Regulatory Framework
 4.6. Company market share analysis, 2018
 4.7. Porter’s Five forces analysis
 4.8. New Investment Analysis
 4.9. PESTEL Analysis
 5. Global Erythropoiesis-Stimulating Agents Market Overview
 5.1. Market Size & Forecast
 5.1.1. Global Erythropoiesis-Stimulating Agents Market By Value (USD)
 5.2. Market Share & Forecast 2015-2025
 5.2.1. By Product Type
 5.2.1.1. Epoetin Alfa
 5.2.1.2. Epoetin Beta
 5.2.1.3. Darbepoetin Alfa
 5.2.1.4. Epoetin-Theta
 5.2.1.5. Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)
 5.2.2. By Application
 5.2.2.1. Cancer
 5.2.2.2. Renal Disorders
 5.2.2.3. Anti-retroviral Treatment
 5.2.2.4. Neural diseases
 5.2.2.5. Others
 5.2.3. By Distribution Channel
 5.2.3.1. Offline Channel
 5.2.3.2. Online Channel
 5.2.4. By Region
 5.2.4.1. North America
 5.2.4.2. Europe
 5.2.4.3. Asia Pacific
 5.2.4.4. South America
 5.2.4.5. Middle East & Africa
 6. North America Erythropoiesis-Stimulating Agents Market
 6.1. North America Erythropoiesis-Stimulating Agents Market Size & Forecast
 6.1.1. By Value (USD)
 6.2. North America Erythropoiesis-Stimulating Agents Market Estimates & Forecast, 2016-2027 (USD Million)
 6.2.1. By Product Type
 6.2.1.1. Epoetin Alfa
 6.2.1.2. Epoetin Beta
 6.2.1.3. Darbepoetin Alfa
 6.2.1.4. Epoetin-Theta
 6.2.1.5. Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)
 6.2.2. By Application
 6.2.2.1. Cancer
 6.2.2.2. Renal Disorders
 6.2.2.3. Anti-retroviral Treatment
 6.2.2.4. Neural diseases
 6.2.2.5. Others
 6.2.3. By Distribution Channel
 6.2.3.1. Offline Channel
 6.2.3.2. Online Channel
 6.2.4. Company Market Share (Top 3-5)
 6.2.5. Economic Impact Study on North America Erythropoiesis-Stimulating Agents Market
 7. Europe Erythropoiesis-Stimulating Agents Market
 7.1. Europe Erythropoiesis-Stimulating Agents Market Size & Forecast
 7.1.1. By Value (USD)
 7.2. Europe Erythropoiesis-Stimulating Agents Market Estimates & Forecast, 2016-2027 (USD Million)
 7.2.1. By Product Type
 7.2.1.1. Epoetin Alfa
 7.2.1.2. Epoetin Beta
 7.2.1.3. Darbepoetin Alfa
 7.2.1.4. Epoetin-Theta
 7.2.1.5. Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)
 7.2.2. By Application
 7.2.2.1. Cancer
 7.2.2.2. Renal Disorders
 7.2.2.3. Anti-retroviral Treatment
 7.2.2.4. Neural diseases
 7.2.2.5. Others
 7.2.3. By Distribution Channel
 7.2.3.1. Offline Channel
 7.2.3.2. Online Channel
 7.2.4. By Country
 7.2.4.1. Germany
 7.2.4.2. U.K
 7.2.4.3. France
 7.2.4.4. Italy
 7.2.4.5. Netherlands
 7.2.4.6. Rest of Europe
 7.2.5. Company Market Share (Top 3-5)
 7.2.6. Economic Impact Study on Europe Erythropoiesis-Stimulating Agents Market
 8. Asia Pacific Erythropoiesis-Stimulating Agents Market
 8.1. Asia Pacific Erythropoiesis-Stimulating Agents Market Size & Forecast
 8.1.1. By Value (USD)
 8.2. Asia Pacific Erythropoiesis-Stimulating Agents Market Estimates & Forecast, 2016-2027 (USD Million)
 8.2.1. By Product Type
 8.2.1.1. Epoetin Alfa
 8.2.1.2. Epoetin Beta
 8.2.1.3. Darbepoetin Alfa
 8.2.1.4. Epoetin-Theta
 8.2.1.5. Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)
 8.2.2. By Application
 8.2.2.1. Cancer
 8.2.2.2. Renal Disorders
 8.2.2.3. Anti-retroviral Treatment
 8.2.2.4. Neural diseases
 8.2.2.5. Others
 8.2.3. By Distribution Channel
 8.2.3.1. Offline Channel
 8.2.3.2. Online Channel
 8.2.4. By Country
 8.2.4.1. China
 8.2.4.2. India
 8.2.4.3. Japan
 8.2.4.4. Australia
 8.2.4.5. South Korea
 8.2.4.6. Rest of Asia Pacific
 8.2.5. Company Market Share (Top 3-5)
 8.2.6. Economic Impact Study on Asia Pacific Erythropoiesis-Stimulating Agents Market
 9. South America Erythropoiesis-Stimulating Agents Market
 9.1. South America Erythropoiesis-Stimulating Agents Market Size & Forecast
 9.1.1. By Value (USD)
 9.2. South America Erythropoiesis-Stimulating Agents Market estimates & forecast, 2016-2027 (USD Million)
 9.2.1. By Product Type
 9.2.1.1. Epoetin Alfa
 9.2.1.2. Epoetin Beta
 9.2.1.3. Darbepoetin Alfa
 9.2.1.4. Epoetin-Theta
 9.2.1.5. Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)
 9.2.2. By Application
 9.2.2.1. Cancer
 9.2.2.2. Renal Disorders
 9.2.2.3. Anti-retroviral Treatment
 9.2.2.4. Neural diseases
 9.2.2.5. Others
 9.2.3. By Distribution Channel
 9.2.3.1. Offline Channel
 9.2.3.2. Online Channel
 9.2.4. By Country
 9.2.4.1. Brazil
 9.2.4.2. Argentina
 9.2.4.3. Rest of South America
 9.2.5. Company Market Share (Top 3-5)
 9.2.6. Economic Impact Study on South America Erythropoiesis-Stimulating Agents Market
 10. Middle East & Africa Erythropoiesis-Stimulating Agents Market
 10.1. Middle East & Africa Market Size & Forecast
 10.1.1. By Value (USD)
 10.2. Middle East & Africa Market estimates & forecast, 2016-2027 (USD Million)
 10.2.1. By Product Type
 10.2.1.1. Epoetin Alfa
 10.2.1.2. Epoetin Beta
 10.2.1.3. Darbepoetin Alfa
 10.2.1.4. Epoetin-Theta
 10.2.1.5. Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)
 10.2.2. By Application
 10.2.2.1. Cancer
 10.2.2.2. Renal Disorders
 10.2.2.3. Anti-retroviral Treatment
 10.2.2.4. Neural diseases
 10.2.2.5. Others
 10.2.3. By Distribution Channel
 10.2.3.1. Offline Channel
 10.2.3.2. Online Channel
 10.2.4. By Country
 10.2.4.1. Saudi Arabia
 10.2.4.2. UAE
 10.2.4.3. South Africa
 10.2.4.4. Rest of Middle East & Africa
 10.2.5. Company Market Share (Top 3-5)
 10.2.6. Economic Impact Study on Middle East & Africa Erythropoiesis-Stimulating Agents Market
 11. Competitor Analysis
 11.1. Company Description
 11.2. Financial Analysis
 11.3. Key Products
 11.4. Key Management Personnel
 11.5. Contact Address
 11.6. SWOT Analysis
 11.7. Company Profiles
 11.7.1. Biocon
 11.7.2. Johnson & Johnson
 11.7.3. Teva Pharmaceutical Industries Ltd.
 11.7.4. Intas Pharmaceuticals
 11.7.5. Amgen Inc.
 11.7.6. Hoffmann-La Roche
 11.7.7. Biosidus
 11.7.8. Thermo Fisher Scientific
 11.7.9. F. Hoffmann La Roche
 11.7.10. Pfizer
 11.7.11. Ranbaxy Laboratories Ltd
 11.7.12. Other Leading Players

Fill The Form For Sample Request

There is no Reviews available